Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study - André, Thierry; Tougeron, David; Piessen, Guillaume; de la Fouchardière, Christelle; Louvet, Christophe; Adenis, Antoine; Jary, Marine; Tournigand, Christophe; Aparicio, Thomas; Desrame, Jérôme; Lièvre, Astrid; Garcia-Larnicol, Marie-Line; et al. (Journal of clinical oncology, 2023)
Keywords: Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Cancer; DNA Mismatch Repair; Esophagogastric Junction - pathology; Human health and pathology; Humans; Hépatology and Gastroenterology; Ipilimumab - therapeutic use; Life Sciences; Microsatellite Instability; Neoadjuvant Therapy; Neoplasm Recurrence, Local - drug therapy; Nivolumab - therapeutic use; ORIGINAL REPORTS; Pharmaceutical sciences; Pharmacology; Santé publique et épidémiologie; Stomach Neoplasms - drug therapy; Stomach Neoplasms - genetics; Stomach Neoplasms - pathology; Adenocarcinoma; clinical trial; Microsatellite Instability; gastroesophageal junction; phase 2 clinical trial; pathology; antineoplastic agent; Humans; Ipilimumab; Antineoplastic Combined Chemotherapy Protocols; Local; mismatch repair; tumor recurrence; Esophagogastric Junction; genetics; DNA Mismatch Repair; Nivolumab; Neoadjuvant Therapy; Aged; Neoplasm Recurrence; Stomach Neoplasms; human; stomach tumor